Pulmonary Circulation最新文献_第3页

Analysis of Clinical Characteristics of 54 Dead Pregnant Patients With Pulmonary Hypertension. 54例妊娠死亡肺动脉高压患者临床特点分析。

IF 2.5 4区医学

Pulmonary Circulation Pub Date : 2025-08-27 eCollection Date: 2025-07-01 DOI: 10.1002/pul2.70123

Lishi Chen, Shenpeng Zhou, Jiaying Wang, Shengchen Hu, Mingmei Xiong

{"title":"Analysis of Clinical Characteristics of 54 Dead Pregnant Patients With Pulmonary Hypertension.","authors":"Lishi Chen, Shenpeng Zhou, Jiaying Wang, Shengchen Hu, Mingmei Xiong","doi":"10.1002/pul2.70123","DOIUrl":"10.1002/pul2.70123","url":null,"abstract":"To analyze the clinical characteristics and potential pregnancy outcomes of deceased pregnant women with pulmonary hypertension, we conducted a retrospective analysis of clinical data from 54 cases of pregnant women with pulmonary hypertension at The Third Affiliated Hospital of Guangzhou Medical University from May 2009 to February 2022. The results demonstrated that (1) Among 54 deceased pregnant patients with pulmonary hypertension (PH), 44 patients belonged to type 1, and 3, 2, and 5 patients belonged to type 2, type 4, and type 5, respectively. In type 1, 33 cases were secondary to congenital heart disease, with ventricular septal defect being common. (2) All 54 patients were diagnosed with PAH during pregnancy or postpartum. NYHA cardiac function grade II (10 cases), Ⅲ (18 cases), Ⅳ (26 cases), heart disease pregnancy risk levels were all Ⅳ. (3) Of the 54 patients, 7 patients had no data on the time of death, and most of them (37 patients) died within 1 week postpartum. (4) These 9 patients with mild PAH death during pregnancy had lower ejection fraction, higher rates of postpartum hemorrhage, left heart failure, systemic failure, arrhythmia, gestational diabetes, and infection than those with moderate or severe PAH death during pregnancy. As a consequence, deaths in pregnancies complicated with PH were mostly caused by PAH crisis, total heart failure, multiple organ failure, Eisenmenger syndrome and maternal perinatal mortality was high. The primary causes of mortality in pregnant women with mild PH include heart failure, respiratory failure, and arrhythmia etc. Patients experiencing complications such as postpartum hemorrhage, left ventricular dysfunction, multiorgan failure, arrhythmia, gestational diabetes mellitus, and infection may have a poorer prognosis.","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"15 3","pages":"e70123"},"PeriodicalIF":2.5,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12382355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144966711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Global, Regional, and National Burden of Pulmonary Arterial Hypertension Among Women of Childbearing Age, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021. 1990-2021年育龄妇女肺动脉高压的全球、地区和国家负担：2021年全球疾病负担研究的系统分析

IF 2.5 4区医学

Pulmonary Circulation Pub Date : 2025-08-20 eCollection Date: 2025-07-01 DOI: 10.1002/pul2.70154

Junjun Liu, Wenjun Wang

{"title":"Global, Regional, and National Burden of Pulmonary Arterial Hypertension Among Women of Childbearing Age, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021.","authors":"Junjun Liu, Wenjun Wang","doi":"10.1002/pul2.70154","DOIUrl":"10.1002/pul2.70154","url":null,"abstract":"Pulmonary arterial hypertension (PAH) is a common condition among women of childbearing age (WCBA) and is associated with adverse outcomes during pregnancy. However, there is currently a lack of studies that provide a detailed epidemiological characterization of this condition. This study aimed to delineate the global burden of pulmonary arterial hypertension (PAH) among women of childbearing age (WCBA) from 1990 to 2021. We utilized the Global Burden of Disease Study 2021 to estimate the prevalence, incidence, mortality, and disability-adjusted life years (DALYs) for PAH among WCBA across 204 countries and territories from 1990 to 2021. Sociodemographic index (SDI) was used to assess the impact of socioeconomic development on PAH burden. In 2021, global estimates revealed 46,630 prevalent cases of PAH, resulting in 8532 new cases, 1777 deaths and 103,151 DALYs. Globally, the age-standardized prevalence, incidence, mortality, and DALY rates for PAH in 2021 stood at 2.35, 0.43, 0.09, and 5.26 per 100,000 population, respectively. In 2021, Switzerland exhibited the highest age-standardized prevalence rate (7.47/100,000). The highest age-standardized incidence rate was observed in Zambia (0.96/100,000). Mauritius reported the highest age-standardized mortality (0.72/100,000) and DALY rates (40.42/100,000), contrasting sharply with Moldova's lowest rates (0.00/100,000 and 0.51/100,000, respectively). At the regional level, the relationship between the SDI and age-standardized prevalence rates for PAH exhibited an approximate V-shaped pattern. The systematic analysis of PAH burden among WCBA underscores the disease's significant global impact and the necessity for continued research and tailored public health strategies, calling for enhanced awareness, improved diagnostics, and more effective treatment modalities, particularly in resource-constrained settings.","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"15 3","pages":"e70154"},"PeriodicalIF":2.5,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144966675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Significance of Pulmonary Vascular Dysfunction in Chronic Obstructive Pulmonary Disease. 慢性阻塞性肺疾病肺血管功能障碍的意义。

IF 2.5 4区医学

Pulmonary Circulation Pub Date : 2025-08-18 eCollection Date: 2025-07-01 DOI: 10.1002/pul2.70144

Steven D Nathan, Lucilla Piccari, Steven H Abman, Aparna Balasubramanian, Reda E Girgis, Gabor Kovacs, Horst Olschewski, Oksana A Shlobin, Norman Stockbridge, S John Wort, George R Washko, Sylvia M Nikkho

{"title":"Significance of Pulmonary Vascular Dysfunction in Chronic Obstructive Pulmonary Disease.","authors":"Steven D Nathan, Lucilla Piccari, Steven H Abman, Aparna Balasubramanian, Reda E Girgis, Gabor Kovacs, Horst Olschewski, Oksana A Shlobin, Norman Stockbridge, S John Wort, George R Washko, Sylvia M Nikkho","doi":"10.1002/pul2.70144","DOIUrl":"10.1002/pul2.70144","url":null,"abstract":"Chronic obstructive pulmonary disease (COPD) is frequently accompanied by abnormalities of the pulmonary vasculature. This vasculopathy spans the spectrum from mild vascular dysfunction to pulmonary hypertension, which on rare occasions can be severe. Given the worldwide prevalence of COPD, it is conceivable that the morbidity and mortality associated with pulmonary vascular dysfunction have been vastly underappreciated, especially in countries and regions where the infrastructure and resources to define the magnitude of the problem are often limited. This article reflects deliberations of the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative (PVRI IDDI) Group 3 Pulmonary Hypertension Workstream on the role of the pulmonary vasculature in COPD. In this introductory paper, we lay the foundation for forthcoming papers by our group, with our ultimate goals being to increase awareness and encourage more research, including clinical trials, to address this unmet need.","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"15 3","pages":"e70144"},"PeriodicalIF":2.5,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12360464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144883521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relationship Between Phenotypical and Echocardiographic Findings With Pulmonary Hypertension in COPD Patients. 慢性阻塞性肺病患者肺动脉高压的表型与超声心动图表现的关系。

IF 2.5 4区医学

Pulmonary Circulation Pub Date : 2025-08-16 eCollection Date: 2025-07-01 DOI: 10.1002/pul2.70153

Sayyed Gholamreza Mortazavi Moghaddam, Fahime Nosrati, Fateme Mahdizadeh, Toba Kazemi, Mohammad Reza Khazdair

{"title":"Relationship Between Phenotypical and Echocardiographic Findings With Pulmonary Hypertension in COPD Patients.","authors":"Sayyed Gholamreza Mortazavi Moghaddam, Fahime Nosrati, Fateme Mahdizadeh, Toba Kazemi, Mohammad Reza Khazdair","doi":"10.1002/pul2.70153","DOIUrl":"10.1002/pul2.70153","url":null,"abstract":"Pulmonary hypertension in COPD patients and identifying accompanying factors in clinical decisions are very important. The current study aimed to determine the relationship between phenotypic and echocardiographic findings with the help of pulmonary artery pressure in patients with COPD. In this study, 100 COPD patients referred to a specialized clinic participated in the study. The prevalence of pulmonary hypertension (PH) and its relationship with phenotypic criteria, spirometry, laboratory findings, and echocardiography in COPD patients were investigated. Among the COPD patients, 76 cases were classified as having chronic bronchitis, nine as having emphysema, and 15 were classified as mixed phenotype by Chest high-resolution computed tomography (HRCT) methods. The prevalence of PH in the study was 36% (moderate 24% and severe 12%). The average pulmonary arterial pressure (PAP) was significantly difference in different phenotypes (p < 0.001). Heart rate and PAP significantly increase in mixed phenotypes p = 0.029 and p = 0.002, respectively. Also, the modified Medical Research Council scale (mMRC) and BODE index were significantly increase in mixed phenotypes of COPD patients (p < 0.05 to p < 0.001). Compared the factors related to PH in different phenotypes of patients with COPD indicated that PH are related with heart rate, PCO2, creatinine, triglycerides, 6MWT and BODE Index.","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"15 3","pages":"e70153"},"PeriodicalIF":2.5,"publicationDate":"2025-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357652/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144874966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FDA Approval of Epoprostenol to Treat Primary Pulmonary Hypertension. FDA批准Epoprostenol治疗原发性肺动脉高压。

IF 2.5 4区医学

Pulmonary Circulation Pub Date : 2025-08-14 eCollection Date: 2025-07-01 DOI: 10.1002/pul2.70149

C Gregory Elliott

引用次数: 0

Predicting Response to Switching From Phosphodiesterase Type 5 Inhibitor to Riociguat in Patients With Pulmonary Arterial Hypertension: Biomarker and Responder Analysis of the RESPITE and REPLACE Studies. 预测肺动脉高压患者从磷酸二酯酶5型抑制剂转向利奥西奎特的反应：RESPITE和REPLACE研究的生物标志物和反应者分析

IF 2.5 4区医学

Pulmonary Circulation Pub Date : 2025-08-14 eCollection Date: 2025-07-01 DOI: 10.1002/pul2.70140

James R Klinger, Hikmet Al-Hiti, Sung-A Chang, Hyuk J Chang, Hossein-Ardeschir Ghofrani, Ekkehard Grünig, Marius M Hoeper, Pavel Jansa, Jaquelina Ota-Arakaki, Tomas Pulido, Gérald Simonneau, Carmine Dario Vizza, Claudia Rahner, Christian Meier, Gisela Meyer

{"title":"Predicting Response to Switching From Phosphodiesterase Type 5 Inhibitor to Riociguat in Patients With Pulmonary Arterial Hypertension: Biomarker and Responder Analysis of the RESPITE and REPLACE Studies.","authors":"James R Klinger, Hikmet Al-Hiti, Sung-A Chang, Hyuk J Chang, Hossein-Ardeschir Ghofrani, Ekkehard Grünig, Marius M Hoeper, Pavel Jansa, Jaquelina Ota-Arakaki, Tomas Pulido, Gérald Simonneau, Carmine Dario Vizza, Claudia Rahner, Christian Meier, Gisela Meyer","doi":"10.1002/pul2.70140","DOIUrl":"10.1002/pul2.70140","url":null,"abstract":"This exploratory analysis assessed whether plasma biomarkers predict the response to switching from phosphodiesterase type 5 inhibitors (PDE5is) to the soluble guanylate cyclase stimulator riociguat in patients with pulmonary arterial hypertension. Selected biomarkers at baseline and their changes to Week 24 were evaluated in patients with and without a favorable response to riociguat in two trials: RESPITE, in which patients with an inadequate response to PDE5i were switched to riociguat; and REPLACE, in which patients at intermediate risk of 1-year mortality despite a PDE5i were randomized to remain on PDE5i or were switched to riociguat. A response was defined as absence of clinical worsening and at least two of the following criteria: 6-min walk distance increase by 10% or ≥ 30 m, World Health Organization functional class I/II, or N-terminal prohormone of brain natriuretic peptide reduction of ≥ 30% at Week 24. In REPLACE, responders had significantly higher baseline cyclic guanosine monophosphate (cGMP) and significantly lower baseline asymmetric dimethylarginine, and growth/differentiation factor 15 (GDF-15) than nonresponders. In RESPITE, responders had lower baseline GDF-15 than nonresponders, and nonresponders showed a significantly greater decrease in cGMP than responders. No baseline threshold value of any biomarker provided a good likelihood of predicting the response to riociguat. Overall, the biomarkers evaluated did not help to identify patients who were more likely to respond to switching from PDE5is to riociguat.","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"15 3","pages":"e70140"},"PeriodicalIF":2.5,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144874965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Genesis and Legacy of the NHLBI Patient Registry for the Characterization of Primary Pulmonary Hypertension (NIH-PPH Registry). NHLBI原发性肺动脉高压患者登记（NIH-PPH登记）的起源和遗产。

IF 2.5 4区医学

Pulmonary Circulation Pub Date : 2025-08-11 eCollection Date: 2025-07-01 DOI: 10.1002/pul2.70148

Harold I Palevsky

引用次数: 0

Effect of Regulating FUNDC1 Mitophagy-Mediated cGAS/STING Pathway in Oleic Acid-Induced Acute Lung Injury Model. 调节FUNDC1线粒体自噬介导的cGAS/STING通路在油酸致急性肺损伤模型中的作用

IF 2.5 4区医学

Pulmonary Circulation Pub Date : 2025-08-06 eCollection Date: 2025-07-01 DOI: 10.1002/pul2.70137

Liangyu Mi, Yuankai Zhou, Wenyan Ding, Xiangyu Chen, Yingying Yang, Qianlin Wang, Lu Wang, Longxiang Su, Yun Long

{"title":"Effect of Regulating FUNDC1 Mitophagy-Mediated cGAS/STING Pathway in Oleic Acid-Induced Acute Lung Injury Model.","authors":"Liangyu Mi, Yuankai Zhou, Wenyan Ding, Xiangyu Chen, Yingying Yang, Qianlin Wang, Lu Wang, Longxiang Su, Yun Long","doi":"10.1002/pul2.70137","DOIUrl":"10.1002/pul2.70137","url":null,"abstract":"Acute lung injury (ALI) involves inflammatory cytokines and chemokines, resulting in lung and multiple organ injuries. This study explored the mechanism of mitophagy and cGAS/STING pathway in oleic acid (OA)-induced ALI. Mice and pulmonary microvascular endothelial cells were divided into four groups: control group (Con), ALI group, FUNDC1 -/- control group (F-Con), and FUNDC1 -/- ALI group (F-ALI). After 24 h of modeling, proceed with tissue collection. Lung tissues were stained using hematoxylin eosin. Autophagosomes were observed by electron microscope and mtDNA was detected by qPCR. Western blot was used to analyze protein expression of pathways cGAS, STING, pTBK1, pIRF3, and pNF-κB. Serum IFN-β expression was detected by ELISA. Cellular morphological changes were observed using microscopy. LDH level, cGAS, and STING in endothelial cells were observed. Compared with control group, pathological changes in ALI group were significantly aggravated. Expressions of serum IFN-β, cGAS, STING, pTBK1, pIRF3, and pNF-κB in lung tissues of ALI mice were significantly higher than control group. After OA, the morphology of lung microvascular endothelial cells changed and LDH expression increased. After FUNDC1 gene was knocked out to inhibit mitophagy, autophagosomes were significantly reduced and mtDNA increased. Expressions of pathway proteins in lung tissues and cells of FUNDC1 -/- ALI group were higher than those of wild-type ALI group. Serum IFN-β expression also increased. Silencing FUNDC1 inhibits mitophagy. Subsequently, accumulated mtDNA activates cGAS/STING pathway, aggravating ALI pathological damage and inflammation, suggesting that mitophagy may provide protection in OA-induced ALI through cGAS/STING pathway.","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"15 3","pages":"e70137"},"PeriodicalIF":2.5,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12326078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144795229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

My Introduction to Pulmonary Hypertension. 我对肺动脉高压的介绍。

IF 2.5 4区医学

Pulmonary Circulation Pub Date : 2025-08-06 eCollection Date: 2025-07-01 DOI: 10.1002/pul2.70124

Harrison W Farber

引用次数: 0

Unraveling Nonenzymatic Nitric Oxide Production and Its Impact on Pulmonary Hypertension. 揭示非酶促一氧化氮产生及其对肺动脉高压的影响。

IF 2.5 4区医学

Pulmonary Circulation Pub Date : 2025-08-05 eCollection Date: 2025-07-01 DOI: 10.1002/pul2.70152

Eric Demoncheaux

引用次数: 0